Publikationen (49) Publikationen von Enrique José Andreu Oltra

2024

  1. A Bioreactor for Celullarised Membrane Culture and Delivery under Sterile Conditions

    Bioengineering, Vol. 11, Núm. 8

2023

  1. Enhanced bioprocess control to advance the manufacture of mesenchymal stromal cell-derived extracellular vesicles in stirred-tank bioreactors

    Biotechnology and Bioengineering, Vol. 120, Núm. 9, pp. 2725-2741

  2. Umbilical cord mesenchymal stromal cells transplantation delays the onset of hyperglycemia in the RIP-B7.1 mouse model of experimental autoimmune diabetes through multiple immunosuppressive and anti-inflammatory responses

    Frontiers in Cell and Developmental Biology, Vol. 11

2022

  1. Optimization of Mesenchymal Stromal Cell (MSC) Manufacturing Processes for a Better Therapeutic Outcome

    Frontiers in Immunology, Vol. 13

2021

  1. Efficacy and safety of intramuscular administration of allogeneic adipose tissue derived and expanded mesenchymal stromal cells in diabetic patients with critical limb ischemia with no possibility of revascularization: study protocol for a randomized controlled double-blind phase II clinical trial (The NOMA Trial)

    Trials, Vol. 22, Núm. 1

  2. Preclinical evaluation of the safety and immunological action of allogeneic ADSC-collagen scaffolds in the treatment of chronic ischemic cardiomyopathy

    Pharmaceutics, Vol. 13, Núm. 8

2020

  1. Adipose-derived mesenchymal stromal cells for the treatment of patients with severe SARS-CoV-2 pneumonia requiring mechanical ventilation. A proof of concept study

    EClinicalMedicine, Vol. 25

  2. Corrigendum: Cost-Effective, Safe, and Personalized Cell Therapy for Critical Limb Ischemia in Type 2 Diabetes Mellitus (Frontiers in Immunology, (2019), 10, 10.3389/fimmu.2019.01151)

    Frontiers in Immunology

  3. Phase II multicenter randomized controlled clinical trial on the efficacy of intra-articular injection of autologous bone marrow mesenchymal stem cells with platelet rich plasma for the treatment of knee osteoarthritis

    Journal of Translational Medicine, Vol. 18, Núm. 1

2019

  1. Cost-effective, safe, and personalized cell therapy for critical limb ischemia in type 2 diabetes mellitus

    Frontiers in Immunology, Vol. 10, Núm. JUN

2018

  1. Intra-articular injection of two different doses of autologous bone marrow mesenchymal stem cells versus hyaluronic acid in the treatment of knee osteoarthritis: Long-term follow up of a multicenter randomized controlled clinical trial (phase I/II)

    Journal of Translational Medicine

2017

  1. A phase II trial of autologous dendritic cell vaccination and radiochemotherapy following fluorescence-guided surgery in newly diagnosed glioblastoma patients

    Journal of Translational Medicine, Vol. 15, Núm. 1

  2. Combined PI3K/Akt and Smad2 activation promotes corneal endothelial cell proliferation

    Investigative Ophthalmology and Visual Science, Vol. 58, Núm. 2, pp. 745-754

  3. Phase 1–2 pilot clinical trial in patients with decompensated liver cirrhosis treated with bone marrow–derived endothelial progenitor cells

    Translational Research, Vol. 188, pp. 80-91.e2

2016

  1. Generation and characterization of human iPSC line generated from mesenchymal stem cells derived from adipose tissue

    Stem Cell Research, Vol. 16, Núm. 1, pp. 20-23

  2. Intra-articular injection of two different doses of autologous bone marrow mesenchymal stem cells versus hyaluronic acid in the treatment of knee osteoarthritis: Multicenter randomized controlled clinical trial (phase I/II)

    Journal of Translational Medicine, Vol. 14, Núm. 1

2015

  1. Efficacy of autologous melanocyte transplantation on amniotic membrane in patientswith stable leukoderma: A randomized clinical trial

    JAMA Dermatology

2014

  1. Quantification of corneal neovascularization after ex vivo limbal epithelial stem cell therapy

    International Journal of Ophthalmology, Vol. 7, Núm. 6, pp. 988-995

  2. Randomized placebo-controlled phase II trial of autologous mesenchymal stem cells in multiple sclerosis

    PLoS ONE, Vol. 9, Núm. 12

  3. Sequential Third-Party Mesenchymal Stromal Cell Therapy for Refractory Acute Graft-versus-Host Disease

    Biology of Blood and Marrow Transplantation, Vol. 20, Núm. 10, pp. 1580-1585